{"commentary":{"count":68,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":37,"podcast":22,"youtube":9},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06320067\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"STAMPEDE2","nct_id":"NCT06320067","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=stampede2-nct06320067. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"STAMPEDE2","arms":[{"description":"SoC (ADT + ARPI ± docetaxel + local RT)","label":"Arm A of SABR Comparison","type":"ACTIVE_COMPARATOR"},{"description":"SoC (ADT + ARPI ± docetaxel + local RT) + SABR","label":"Arm S of SABR Comparison","type":"EXPERIMENTAL"},{"description":"SoC (ADT + ARPI ± docetaxel ± local RT)","label":"Arm A of 177Lu-PSMA-617 Comparison","type":"ACTIVE_COMPARATOR"},{"description":"SoC (ADT + ARPI ± docetaxel ± local RT) + 177Lu-PSMA-617","label":"Arm P of 177Lu-PSMA-617 Comparison","type":"EXPERIMENTAL"}],"collaborators":["Cancer Research UK","Novartis"],"completion_date":{"date":"2032-03","type":"ESTIMATED"},"conditions":["Prostate Cancer Metastatic"],"enrollment":{"count":3360,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Stereotactic Ablative Body Radiotherapy (SABR)","type":"RADIATION"},{"name":"177Lu-PSMA-617","type":"OTHER"},{"name":"Androgen Deprivation Therapy (ADT)","type":"DRUG"},{"name":"Androgen Receptor Signalling Inhibitor (ARPI)","type":"DRUG"},{"name":"Radiotherapy to Prostate ± Pelvic Nodes","type":"RADIATION"},{"name":"Docetaxel","type":"DRUG"}],"last_update":"2025-09-26","lead_sponsor":"University College, London","official_title":"Studying Treatments in Patients Receiving Androgen Deprivation Therapy (ADT) for Metastatic Prostate Cancer: Evaluation of Drug and Radiation Efficacy: A 2nd Multi-arm Multi-stage Randomised Controlled Trial (STAMPEDE2).","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2031-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Final analysis for each comparison triggered when adequate number of death events have occurred in control arm of each comparison. Anticipate final reporting for OS in Comparison S: ~84 months (7 years) from FPFV, P: ~64 months (5.3 years) from FPFV."}],"references":[],"start_date":{"date":"2024-06-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT06320067"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/stampede2-nct06320067"}